Authors:
Leonel Hernandez-Aya1, Estelamari Rodriguez1, Aparna Nallagangula1, Jun Yin2, Phillip Walker2, Joanne Xiu2, Justin Moser3, Gino K. In4, David Spetzler2, Geoffery T. Gibney5, Matthew Oberley2, Thuy Phung6, Michael Atkins6, Dave S. Hoon7, Wolfgang Michael Korn2, Jose Lutzky1, Gilberto Lopes1.
Background
Activation in RAS pathway has been associated with cancer development. The oncogenes of RAS family (NRAS, KRAS and HRAS) are frequently mutated across various cancer types, where NRAS mutations are present in 15-20% of melanomas. NRAS-mutant melanomas (NRASm) have been extensively characterized. However, molecular and clinical implications of HRAS mutations (HRASm) in melanoma are less well understood.
Download PublicationCookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |